JP6901787B2 - 改善されたｎｒｆ２活性化のための組成物及びその使用方法 - Google Patents

改善されたｎｒｆ２活性化のための組成物及びその使用方法 Download PDF

Info

Publication number
JP6901787B2
JP6901787B2 JP2018531303A JP2018531303A JP6901787B2 JP 6901787 B2 JP6901787 B2 JP 6901787B2 JP 2018531303 A JP2018531303 A JP 2018531303A JP 2018531303 A JP2018531303 A JP 2018531303A JP 6901787 B2 JP6901787 B2 JP 6901787B2
Authority
JP
Japan
Prior art keywords
extract
luteolin
nrf2
composition
rosemary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018531303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529763A (ja
JP2018529763A5 (enExample
Inventor
ブルックス マイケル ハイバートソン，
ブルックス マイケル ハイバートソン，
ジョー ミルトン マッコード，
ジョー ミルトン マッコード，
Original Assignee
パスウェイズ バイオサイエンス， エルエルシー
パスウェイズ バイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パスウェイズ バイオサイエンス， エルエルシー, パスウェイズ バイオサイエンス， エルエルシー filed Critical パスウェイズ バイオサイエンス， エルエルシー
Publication of JP2018529763A publication Critical patent/JP2018529763A/ja
Publication of JP2018529763A5 publication Critical patent/JP2018529763A5/ja
Application granted granted Critical
Publication of JP6901787B2 publication Critical patent/JP6901787B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2018531303A 2015-09-03 2016-09-02 改善されたｎｒｆ２活性化のための組成物及びその使用方法 Active JP6901787B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562214175P 2015-09-03 2015-09-03
US62/214,175 2015-09-03
US201662355810P 2016-06-28 2016-06-28
US62/355,810 2016-06-28
PCT/US2016/050292 WO2017041054A1 (en) 2015-09-03 2016-09-02 Compositions for improved nrf2 activation and methods of their use

Publications (3)

Publication Number Publication Date
JP2018529763A JP2018529763A (ja) 2018-10-11
JP2018529763A5 JP2018529763A5 (enExample) 2019-10-10
JP6901787B2 true JP6901787B2 (ja) 2021-07-14

Family

ID=58188643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531303A Active JP6901787B2 (ja) 2015-09-03 2016-09-02 改善されたｎｒｆ２活性化のための組成物及びその使用方法

Country Status (9)

Country Link
US (1) US11413269B2 (enExample)
JP (1) JP6901787B2 (enExample)
CN (2) CN120754114A (enExample)
CL (1) CL2018000573A1 (enExample)
CO (1) CO2018003454A2 (enExample)
HK (1) HK1256480A1 (enExample)
MX (2) MX394479B (enExample)
PE (1) PE20190380A1 (enExample)
WO (1) WO2017041054A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220354916A1 (en) * 2015-09-03 2022-11-10 Pathways Bioscience, Llc Compositions for improved nrf2 activation and methods of their use
US10993981B2 (en) * 2016-07-11 2021-05-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organiation (Aro), (Volcani Center) Compositions for treatment of follicular tonsillitis using an emulsion based on rosemary extract and oregano essential oil
CN110545831A (zh) * 2017-04-27 2019-12-06 帝斯曼知识产权资产管理有限公司 Withania somnifera提取物提供针对空气污染相关疾病的保护的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
US9265808B2 (en) * 2004-03-23 2016-02-23 Lifeline Nutraceuticals Corporation Compositions for alleviating inflammation and oxidative stress in a mammal
WO2006073042A1 (ja) * 2005-01-05 2006-07-13 Toagosei Co., Ltd. Ｎｒｆ２依存遺伝子の活性化剤
CN101460185A (zh) * 2006-04-03 2009-06-17 雀巢产品技术援助有限公司 用于促进骨生长和维持骨健康的营养组合物及与其有关的方法
US8142806B2 (en) 2008-03-10 2012-03-27 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
CN102164508B (zh) 2008-07-31 2015-04-01 嘉康利公司 具有增加的抗氧化活性的麝香葡萄组合物
JP2011057654A (ja) * 2009-09-14 2011-03-24 Iwate Univ メタボリックシンドローム治療又は予防薬、及び脂肪細胞分化抑制方法
CA2785581A1 (en) 2009-12-24 2011-06-30 Stanley Kubow Compositions and methods for preventing and treating diseases and environmentally induced health disorders
KR101254847B1 (ko) * 2010-05-27 2013-04-15 한림대학교 산학협력단 실리비닌(silibinin)을 포함하는 골다공증 치료 및 예방용 조성물
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
CN104540513B (zh) * 2012-01-16 2019-04-05 赫克托·德·杰休斯·维莱斯-里韦拉 用于治疗与关节疾病相关疼痛的植物组合物
JP2013209351A (ja) 2012-03-30 2013-10-10 Sunstar Inc 抗酸化機能亢進剤
US20140287071A1 (en) * 2013-01-17 2014-09-25 Lifevantage Corporation Veterinary supplements
WO2014151891A1 (en) * 2013-03-14 2014-09-25 Walley Darlene Topical products
AU2014291615B2 (en) * 2013-07-17 2019-09-26 Council Of Scientific & Industrial Research Pharmaceutical composition for the treatment of diminution of bone tissue
WO2016037971A1 (en) * 2014-09-08 2016-03-17 Bios Line S.P.A. Compositions comprising glucosinolates precursors of sulforaphane in combination with extracts of rosemary

Also Published As

Publication number Publication date
PE20190380A1 (es) 2019-03-08
HK1256480A1 (zh) 2019-09-27
MX394479B (es) 2025-03-24
CN108136209A (zh) 2018-06-08
JP2018529763A (ja) 2018-10-11
CN120754114A (zh) 2025-10-10
MX2018002743A (es) 2018-06-06
US20180250264A1 (en) 2018-09-06
US11413269B2 (en) 2022-08-16
MX2022009446A (es) 2022-09-05
CO2018003454A2 (es) 2018-08-31
WO2017041054A1 (en) 2017-03-09
CL2018000573A1 (es) 2019-01-11

Similar Documents

Publication Publication Date Title
Raina et al. Potential of Juniperus communis L as a nutraceutical in human and veterinary medicine
Lum et al. Protective effect of natural products against Huntington’s disease: An overview of scientific evidence and understanding their mechanism of action
Lila et al. Health‐related interactions of phytochemicals
Wang et al. Recent advances in natural therapeutic approaches for the treatment of cancer
Einbond et al. Carnosic acid inhibits the growth of ER-negative human breast cancer cells and synergizes with curcumin
Acharya et al. Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis
US20100209388A1 (en) Nutraceutical composition and method of use for treatment / prevention of cancer
Seo et al. Curcumin as a putative antidepressant
Roy et al. Anti-inflammatory effects of different dietary antioxidants
US20060035981A1 (en) Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
Fouad et al. Hepatotoxicity and renal toxicity induced by gamma-radiation and the modulatory protective effect of Ficus carica in male albino rats
Ralhan et al. Nuclear factor-kappa B links carcinogenic and chemopreventive agents
Kirdeeva et al. How should the worldwide knowledge of traditional cancer healing be integrated with herbs and mushrooms into modern molecular pharmacology?
Ali et al. Recent advances in the pharmacological properties and molecular mechanisms of carvacrol
Ravichandra et al. Anticancer plants: chemistry, pharmacology, and potential applications
JP6901787B2 (ja) 改善されたｎｒｆ２活性化のための組成物及びその使用方法
Gupta et al. Beating cancer with natural plant sources
Metwally et al. Kaempferol: Advances on Resources, Biosynthesis Pathway, Bioavailability, Bioactivity, and Pharmacology
Koo et al. Effects of red ginseng on the regulation of cyclooxygenase-2 of spleen cells in whole-body gamma irradiated mice
Karthika et al. Incorporation of natural assumption to deal with cancer
Mattathi et al. Exploring the Potential of Dietary Phytochemicals in Cancer Therapeutics: Modulating Apoptosis and Autophagy
Fazeli-Nasab et al. Medicinal Plants and Herbal Compounds: Cancer Prevention and Treatment
Cassé Molecular mechanisms of Annona muricata anti-proliferative/anti-cancer properties
US20220354916A1 (en) Compositions for improved nrf2 activation and methods of their use
Gupta et al. Advances in nutraceutical applications in cancer: recent research trends and clinical applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210506

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210611

R150 Certificate of patent or registration of utility model

Ref document number: 6901787

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250